Home/PathAI/Dr. Andrew Beck
DA

Dr. Andrew Beck

Co-Founder & CEO

PathAI

PathAI Pipeline

DrugIndicationPhase
AIM-PDL1Various Cancers (Immunotherapy Biomarker)Development/Commercial
AIM-HER2Breast CancerDevelopment/Commercial
AIM-MASHMetabolic dysfunction-Associated SteatohepatitisFDA Qualified for Trials
AIM-HI-UCUlcerative ColitisClinical Trials
AISight® DxPrimary Diagnosis (Platform)FDA Cleared